Metabolix, Inc. Share Price Nasdaq
Equities
US5910188821
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
15/05 | Earnings Flash (YTEN) YIELD10 BIOSCIENCE Posts Q1 Revenue $300,000 | MT |
15/05 | Top Midday Decliners | MT |
Sales 2024 * | 2.25M 187M | Sales 2025 * | 4M 333M | Capitalization | 1.36M 113M |
---|---|---|---|---|---|
Net income 2024 * | -11M -916M | Net income 2025 * | -13M -1.08B | EV / Sales 2024 * | 0.6 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.34 x |
P/E ratio 2024 * |
-0.12
x | P/E ratio 2025 * |
-0.1
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
Latest transcript on Metabolix, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Oliver Peoples
FOU | Founder | 66 | 01/92/01 |
Charles Haaser
DFI | Director of Finance/CFO | 68 | 01/08/01 |
Kristi Snell
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/97/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 67 | 01/06/01 | |
Richard Hamilton
BRD | Director/Board Member | 61 | 02/17/02 |
Oliver Peoples
FOU | Founder | 66 | 01/92/01 |
1st Jan change | Capi. | |
---|---|---|
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |